D. Scollard, L. Adams, T. Gillis, J. Krahenbuhl, and R. Truman, The Continuing Challenges of Leprosy, Clinical Microbiology Reviews, vol.19, issue.2, pp.338-381, 2006.
DOI : 10.1128/CMR.19.2.338-381.2006

J. Richardus and J. Habbema, The impact of leprosy control on the transmission of M. leprae: is elimination being attained?, Lepr Rev, vol.78, pp.330-337, 2007.

E. You, T. Kang, S. Kim, S. Lee, and C. , Mutations in genes related to drug resistance in Mycobacterium leprae isolates from leprosy patients in Korea, Journal of Infection, vol.50, issue.1, pp.6-11, 2005.
DOI : 10.1016/j.jinf.2004.03.012

M. Matsuoka, T. Budiawan, K. Aye, K. Kyaw, and E. Tan, The frequency of drug resistance mutations in Mycobacterium leprae isolates in untreated and relapsed leprosy patients from Myanmar, Indonesia and the Philippines, Lepr Rev, vol.78, pp.343-352, 2007.

C. Guelpa-lauras, J. Cartel, M. Constant-desportes, J. Millan, and P. Bobin, Primary and secondary dapsone resistance of M. leprae in Martinique, Int J Lepr Other Mycobact Dis, vol.55, pp.672-679, 1980.

J. Chen, S. Wang, Y. Hou, G. Ni, and J. Zhang, Primary dapsone resistance in China, Lepr Rev, vol.60, pp.263-266, 1989.

J. Grosset, C. Guelpa-lauras, P. Bobin, G. Brucker, and J. Cartel, Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin, Int J Lepr Other Mycobact Dis, vol.57, pp.607-614, 1989.

B. Ji and J. Grosset, Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy, Leprosy Review, vol.71, pp.81-87, 2000.
DOI : 10.5935/0305-7518.20000074

E. Cambau, P. Bonnafous, E. Perani, W. Sougakoff, and B. Ji, Molecular Detection of Rifampin and Ofloxacin Resistance for Patients Who Experience Relapse of Multibacillary Leprosy, Clin Infect Dis, vol.34, pp.39-45, 2002.

F. Pardillo, J. Burgos, T. Fajardo, D. Cruz, E. Abalos et al., Powerful Bactericidal Activity of Moxifloxacin in Human Leprosy, Antimicrobial Agents and Chemotherapy, vol.52, issue.9, pp.3113-3117, 2008.
DOI : 10.1128/AAC.01162-07

E. Cambau, E. Perani, I. Guillemin, P. Jamet, and J. B. , Multidrug-resistance to dapsone, rifampicin, and ofloxacin in Mycobacterium leprae, The Lancet, vol.349, issue.9045, pp.103-104, 1997.
DOI : 10.1016/S0140-6736(05)60888-4

S. Maeda, M. Matsuoka, N. Nakata, M. Kai, and Y. Maeda, Multidrug Resistant Mycobacterium leprae from Patients with Leprosy, Antimicrobial Agents and Chemotherapy, vol.45, issue.12, pp.3635-3639, 2001.
DOI : 10.1128/AAC.45.12.3635-3639.2001

S. Kim, S. Lee, T. Kang, and C. , from leprosy patients using Touch-Down (TD) PCR, FEMS Immunology & Medical Microbiology, vol.36, issue.1-2, pp.27-32, 2003.
DOI : 10.1016/S0928-8244(03)00038-5

S. Matrat, E. Cambau, V. Jarlier, and A. A. , Are All the DNA Gyrase Mutations Found in Mycobacterium leprae Clinical Strains Involved in Resistance to Fluoroquinolones?, Antimicrobial Agents and Chemotherapy, vol.52, issue.2, pp.745-747, 2008.
DOI : 10.1128/AAC.01095-07

K. Yokoyama, H. Kim, T. Mukai, M. Matsuoka, and C. Nakajima, Impact of Amino Acid Substitutions in B Subunit of DNA Gyrase in Mycobacterium leprae on Fluoroquinolone Resistance, PLoS Neglected Tropical Diseases, vol.6, issue.10, p.1838, 2012.
DOI : 10.1371/journal.pntd.0001838.s004

K. Yokoyama, H. Kim, T. Mukai, M. Matsuoka, and C. Nakajima, Amino Acid Substitutions at Position 95 in GyrA Can Add Fluoroquinolone Resistance to Mycobacterium leprae, Antimicrobial Agents and Chemotherapy, vol.56, issue.2, pp.697-702, 2012.
DOI : 10.1128/AAC.05890-11

M. Matsuoka, Y. Kashiwabara, Z. Liangfen, M. Goto, and S. Kitajima, A Second Case of Multidrug-resistant Mycobacterium leprae Isolated from a Japanese Patient with Relapsed Lepromatous Leprosy, International Journal of Leprosy and Other Mycobacterial Diseases, vol.71, issue.3, p.240, 2003.
DOI : 10.1489/1544-581X(2003)71<240:ASCOMM>2.0.CO;2

D. Silva-rocha, A. Cunha, M. , G. Diniz, L. Salgado et al., Drug and Multidrug Resistance among Mycobacterium leprae Isolates from Brazilian Relapsed Leprosy Patients, Journal of Clinical Microbiology, vol.50, issue.6, pp.1912-1917, 2012.
DOI : 10.1128/JCM.06561-11

M. Colston, G. Hilson, and D. Banerjee, The ''proportional bactericidal test'': a method for assessing bactericidal activity in drugs against Mycobacterium leprae in mice, Lepr Rev, vol.49, pp.7-15, 1978.

C. Shepard and D. Mcrae, A method for counting acid-fast bacteria, Int J Lepr Other Mycobact Dis, vol.36, pp.78-82, 1968.

C. Shepard, Statistical analysis of results obtained by two methods for testing drug activity against Mycobacterium leprae, Int J Lepr Other Mycobact Dis, vol.50, pp.96-101, 1982.

S. Woods and S. Cole, A rapid method for the detection of potentially viable Mycobacterium leprae in human biopsies: a novel application of PCR, FEMS Microbiol Lett, vol.53, pp.305-309, 1989.

M. Matsuoka, Y. Kashiwabara, and M. Namisato, A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin, Int J Lepr Other Mycobact Dis, vol.68, pp.452-455, 2000.

S. Consigny, A. Bentoucha, P. Bonnafous, J. Grosset, and J. B. , Bactericidal Activities of HMR 3647, Moxifloxacin, and Rifapentine against Mycobacterium leprae in Mice, Antimicrobial Agents and Chemotherapy, vol.44, issue.10, pp.2919-2921, 2000.
DOI : 10.1128/AAC.44.10.2919-2921.2000

B. Ji, A. Chauffour, K. Andries, and V. Jarlier, Bactericidal Activities of R207910 and Other Newer Antimicrobial Agents against Mycobacterium leprae in Mice, Antimicrobial Agents and Chemotherapy, vol.50, issue.4, pp.1558-1560, 2006.
DOI : 10.1128/AAC.50.4.1558-1560.2006

S. Matrat, S. Petrella, E. Cambau, W. Sougakoff, and V. Jarlier, Expression and Purification of an Active Form of the Mycobacterium leprae DNA Gyrase and Its Inhibition by Quinolones, Antimicrobial Agents and Chemotherapy, vol.51, issue.5, pp.1643-1648, 2007.
DOI : 10.1128/AAC.01282-06

E. Azoulay-dupuis, J. Bédos, J. Mohler, G. Peytavin, and R. Isturiz, Activities of Garenoxacin against Quinolone-Resistant Streptococcus pneumoniae Strains In Vitro and in a Mouse Pneumonia Model, Antimicrobial Agents and Chemotherapy, vol.48, issue.3, pp.765-773, 2004.
DOI : 10.1128/AAC.48.3.765-773.2004

K. Yamamoto, K. Yanagihara, K. Sugahara, Y. Imamura, and M. Seki, In Vitro Activity of Garenoxacin against Streptococcus pneumoniae Mutants with Characterized Resistance Mechanisms, Antimicrobial Agents and Chemotherapy, vol.53, issue.8, pp.3572-3575, 2009.
DOI : 10.1128/AAC.00176-09

H. Suzuki, T. Nishizawa, H. Muraoka, and T. Hibi, Sitafloxacin and Garenoxacin May Overcome the Antibiotic Resistance of Helicobacter pylori with gyrA Mutation, Antimicrobial Agents and Chemotherapy, vol.53, issue.4, pp.1720-1721, 2009.
DOI : 10.1128/AAC.00049-09

Y. Fukuda, M. Takahata, Y. Sugiura, Y. Shinmura, and N. Nomura, In vitro pharmacodynamic evaluation of garenoxacin against quinolone-resistant Streptococcus pneumoniae, International Journal of Antimicrobial Agents, vol.39, issue.2, pp.163-167, 2012.
DOI : 10.1016/j.ijantimicag.2011.09.021

M. Gidoh, In vitro and in vivo activities of moxifloxacin and garenoxacin against Mycobacterium leprae, Japanese journal of leprosy, vol.76, issue.1, pp.11-17, 2007.
DOI : 10.5025/hansen.76.11

A. European-medicines, Questions and answers on the withdrawal of the marketing application for Garenoxain Mesylate, 2007.

J. Poissy, A. A. Fernandez, C. Lott, M. Chauffour, and A. , Should Moxifloxacin Be Used for the Treatment of Extensively Drug-Resistant Tuberculosis? An Answer from a Murine Model, Antimicrobial Agents and Chemotherapy, vol.54, issue.11, pp.4765-4771, 2010.
DOI : 10.1128/AAC.00968-10

S. Matrat, N. Veziris, C. Mayer, V. Jarlier, and C. Truffot-pernot, Functional Analysis of DNA Gyrase Mutant Enzymes Carrying Mutations at Position 88 in the A Subunit Found in Clinical Strains of Mycobacterium tuberculosis Resistant to Fluoroquinolones, Antimicrobial Agents and Chemotherapy, vol.50, issue.12, pp.4170-4173, 2006.
DOI : 10.1128/AAC.00944-06

B. Ji, E. Perani, C. Petinom, and J. Grosset, Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice, Antimicrob Agents Chemother, vol.40, pp.393-399, 1996.

B. Ji, P. Jamet, E. Perani, S. Sow, and C. Lienhardt, Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients, Antimicrob Agents Chemother, vol.40, pp.2137-2141, 1996.

J. Stambaugh, S. Berning, A. Bulpitt, E. Hollender, and M. Narita, Ofloxacin population pharmacokinetics in patients with tuberculosis, Int J Tuberc Lung Dis, vol.6, pp.503-509, 2002.

J. Grosset, C. Guelpa-lauras, E. Perani, and C. Beoletto, Activity of ofloxacin against Mycobacterium leprae in the mouse, Int J Lepr Other Mycobact Dis, vol.56, pp.259-264, 1988.

A. Lubasch, I. Keller, K. Borner, P. Koeppe, and H. Lode, Comparative Pharmacokinetics of Ciprofloxacin, Gatifloxacin, Grepafloxacin, Levofloxacin, Trovafloxacin, and Moxifloxacin after Single Oral Administration in Healthy Volunteers, Antimicrobial Agents and Chemotherapy, vol.44, issue.10, pp.2600-2603, 2000.
DOI : 10.1128/AAC.44.10.2600-2603.2000

D. Andes and W. Craig, Pharmacodynamics of the New Des-F(6)-Quinolone Garenoxacin in a Murine Thigh Infection Model, Antimicrobial Agents and Chemotherapy, vol.47, issue.12, pp.3935-3941, 2003.
DOI : 10.1128/AAC.47.12.3935-3941.2003

D. Gajjar, A. Bello, Z. Ge, L. Christopher, and D. Grasela, Multiple-Dose Safety and Pharmacokinetics of Oral Garenoxacin in Healthy Subjects, Antimicrobial Agents and Chemotherapy, vol.47, issue.7, pp.2256-2263, 2003.
DOI : 10.1128/AAC.47.7.2256-2263.2003

P. Davey, The pharmacokinetics of clarithromycin and its 14-OH metabolite, Journal of Hospital Infection, vol.19, pp.29-37, 1991.
DOI : 10.1016/0195-6701(91)90215-T

P. Tessier, M. Kim, W. Zhou, D. Xuan, and C. Li, Pharmacodynamic Assessment of Clarithromycin in a Murine Model of Pneumococcal Pneumonia, Antimicrobial Agents and Chemotherapy, vol.46, issue.5, pp.1425-1434, 2002.
DOI : 10.1128/AAC.46.5.1425-1434.2002

E. Cambau, A. Chauffour-nevejans, L. Tejmar-kolar, M. Matsuoka, and V. Jarlier, Detection of Antibiotic Resistance in Leprosy Using GenoType LepraeDR, a Novel Ready-To-Use Molecular Test, PLoS Neglected Tropical Diseases, vol.6, issue.7, p.1739, 2012.
DOI : 10.1371/journal.pntd.0001739.t003

M. Matsuoka, Y. Suzuki, E. Garcia, I. Fafutis-morris, M. Vargas-gonzález et al., Possible Mode of Emergence for Drug-Resistant Leprosy Is Revealed by an Analysis of Samples from Mexico, Jpn J Infect Dis, vol.63, pp.412-416, 2010.